New and Evolving Therapeutic Targets in Lung Cancer: Expert Guidance in Incorporating Biomarker Testing to Deliver Precision Therapy

Download All
Gain expert insights on how to test for new and emerging molecular targets and incorporate targeted agents into the care of your patients with lung cancer with downloadable slides and on-demand Webcasts from live meetings, biomarker summary handouts, and a decision support tool providing the latest individualized guidance on precision therapy for NSCLC.
person default
Maria E. Arcila, MD
Leora Horn, MD, MSc, FRCPC
Edward S. Kim, MD, FACP, FASCO
Helena A. Yu, MD

Podcast Pearls

Key insights from our podcast featuring expert answers to questions on biomarker testing and selecting targeted therapies for patients with advanced NSCLC.

Released: August 10, 2020

Highlights from our podcast featuring expert answers to questions on current and evolving biomarkers for immune checkpoint inhibitor–based therapies in patients with advanced NSCLC.

Leora Horn, MD, MSc, FRCPC Edward S. Kim, MD, FACP, FASCO Released: August 10, 2020

Highlights from our podcast featuring a medical oncologist and molecular pathologist discussing key data from ESMO 2020 informing precision medicine in NSCLC.

person default Maria E. Arcila, MD Helena A. Yu, MD Released: December 21, 2020

Highlights from our podcast featuring a medical oncologist and molecular pathologist discussing best practices when testing for actionable biomarkers in NSCLC.

Released: December 29, 2020
Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings